株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗肥満薬の米国市場:2015-2019年

Anti-obesity Drugs Market in the US 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 336069
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
抗肥満薬の米国市場:2015-2019年 Anti-obesity Drugs Market in the US 2015-2019
出版日: 2015年07月22日 ページ情報: 英文 82 Pages
概要

米国の抗肥満薬市場は2014年から2019年にかけて24.52%のCAGRで成長すると予測されています。

当レポートでは、米国の抗肥満薬の市場について調査し、肥満症の概要、主な製品のプロファイル、市場規模の推移と予測、抗肥満薬の薬剤クラスと投薬タイプ、市場成長への各種影響因子の分析、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語集

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 製品プロファイル

  • Xenical
  • Qsymia
  • Belviq
  • Saxenda
  • Contrave

第5章 市場調査手法

第6章 イントロダクション

第7章 疾患概要

  • 疾患について
  • 病因・併存疾患
  • 肥満症の分類
  • 疫学
  • 肥満症の経済的負担

第8章 市場環境

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第9章 抗肥満薬の薬剤クラス

  • 末梢作用性抗肥満薬
  • 中枢作用性抗肥満薬

第10章 抗肥満薬の投薬タイプ

  • 単剤療法
  • 多剤併用療法

第11章 購入基準

第12章 市場成長推進因子

第13章 成長推進因子とその影響

第14章 市場における課題

第15章 成長推進因子と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー環境

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Vivus
    • Arena Pharmaceuticals
    • Orexigen Therapeutics
    • Novo Nordisk
  • 他の有力ベンダー

第19章 主要ベンダーの分析

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus
  • Novo Nordisk
    • 主要データ
    • 事業概要
    • 事業別収益
    • 地域別収益
    • 事業戦略
    • 近年の発展動向
    • SWOT分析、など

第20章 関連レポート

図表

目次
Product Code: IRTNTR6729

About Obesity

Obesity is a complex multifactorial disorder characterized by the excessive accumulation and storage of fat in the body. In the recent years, this chronic illness is being considered as a global epidemic owing to its strikingly increasing incidence rates, especially in the in low and middle-income countries. Sedentary lifestyles and lack of physical activity coupled with consumption of high-calorie diet are considered to be the most preventable causes of obesity. Being either overweight or obese is considered as a risk factor for the development of multiple chronic diseases including cardiovascular disorders such as coronary heart disease, dyslipidemia, hypertension; metabolic disorders such as diabetes; and cancers to highlight a few. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

Technavio's analysts forecast the anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity.

Technavio's report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the

key vendors operating in this market.

Key Vendors

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novo Nordisk
  • Orexigen Therapeutics
  • Vivus

Other Prominent Vendors

  • Alizyme
  • Amylin
  • Boehringer Ingelheim
  • Eisai
  • Merck
  • Norgine
  • Pfizer
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceutical
  • Zafgan

Key Market Driver

  • Growing Prevalence Population
  • For a full, detailed list, view our report

Key Market Challenge

  • Serious Adverse Events and Multiple Drug Withdrawals
  • For a full, detailed list, view our report

Key Market Trend

  • Diversification of Investigational Pipeline
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

  • 04.1. Xenical
  • 04.2. Qsymia
  • 04.3. Belviq
  • 04.4. Saxenda
  • 04.5. Contrave

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

    • 07.1.1. Understanding the Disease
    • 07.1.2. Etiology and Comorbidities
    • 07.1.3. Classification of Obesity
    • 07.1.4. Epidemiology
    • 07.1.5. Economic Burden Due to Obesity

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Drug Class

  • 09.1. Peripherally Acting Anti-obesity Drugs
  • 09.2. Centrally Acting Anti-obesity Drugs

10. Market Segmentation by Medication Type

  • 10.1. Monotherapies
  • 10.2. Polytherapies

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and Their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and Their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. F. Hoffmann-La Roche
    • 18.2.2. GlaxoSmithKline
    • 18.2.3. Vivus
    • 18.2.4. Arena Pharmaceuticals
    • 18.2.5. Orexigen Therapeutics
    • 18.2.6. Novo Nordisk
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Arena Pharmaceuticals
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Geographical Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Recent Developments
    • 19.1.6. SWOT Analysis
  • 19.2. F. Hoffmann-La Roche
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2012 and 2013
    • 19.2.5. Geographical Segmentation by Revenue
    • 19.2.6. Business Strategy
    • 19.2.7. Key Information
    • 19.2.8. SWOT Analysis
  • 19.3. GlaxoSmithKline
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Pipeline Products
    • 19.3.7. Business Strategy
    • 19.3.8. Key Information
    • 19.3.9. SWOT Analysis
  • 19.4. Orexigen Therapeutics
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Strategy
    • 19.4.4. Recent Developments
    • 19.4.5. SWOT Analysis
  • 19.5. Vivus
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Geographical Segmentation by Revenue 2013
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Information
    • 19.5.8. SWOT Analysis
  • 19.6. Novo Nordisk
    • 19.6.1. Key Facts
    • 19.6.2. Business Overview
    • 19.6.3. Business Segmentation by Revenue 2013
    • 19.6.4. Business Segmentation by Revenue 2012 and 2013
    • 19.6.5. Sales by Geography
    • 19.6.6. Business Strategy
    • 19.6.7. Key Information
    • 19.6.8. SWOT Analysis

20. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Causes and Comorbidities of Obesity
  • Exhibit 3: Prevalence of Adults Overweight or Obese in US
  • Exhibit 4: Prevalence of Adults Overweight or Obese in US
  • Exhibit 5: Prevalence Rate of Children Overweight or Obese in US
  • Exhibit 6: Anti-obesity Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 7: Segmentation of Anti-obesity Drugs Market in US by Drug Class
  • Exhibit 8: Segmentation of Anti-obesity Drugs Market in US by Medication Type
  • Exhibit 9: Pipeline Snapshot
  • Exhibit 10: Key Takeaways: F. Hoffman-La Roche
  • Exhibit 11: Key Takeaways: GlaxoSmithKline
  • Exhibit 12: Key Takeaways: Vivus
  • Exhibit 13: Key Takeaways: Arena Pharmaceuticals
  • Exhibit 14: Key Takeaways: Orexigen
  • Exhibit 15: Key Takeaways: Novo Nordisk
  • Exhibit 16: Arena Pharmaceuticals: Geographical Segmentation
  • Exhibit 17: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 18: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 19: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
  • Exhibit 20: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
  • Exhibit 21: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 22: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 23: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 24: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 25: Vivus: Business Segmentation by Revenue 2013
  • Exhibit 26: Vivus: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 27: Vivus: Geographical Segmentation by Revenue 2013
  • Exhibit 28: Novo Nordisk: Business Segmentation by Revenue 2013
  • Exhibit 29: Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 30: Novo Nordisk: Sales by Geography 2013
Back to Top